- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06255782
Une étude ouverte pour étudier l'ECUR-506 chez les bébés mâles de moins de 9 mois présentant un déficit néonatal en vente libre (OTC-HOPE)
Une première étude de phase I/II chez l'homme, ouverte, à dose croissante pour évaluer l'innocuité et l'efficacité d'une administration intraveineuse (IV) unique d'ECUR-506 chez des hommes de moins de 9 mois avec un début néonatal génétiquement confirmé Déficit en ornithine transcarbamylase (OTC)
Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxifying of ammonia. Individuals with OTC deficiency can develop elevated levels of ammonia in the blood, potentially resulting in severe consequences, including cumulative and irreversible neurological damage, coma, and death. The most severe form presents shortly after birth and occurs more commonly in boys than girls.
This is a Phase 1/2/3, open-label, multicenter study evaluating the safety, efficacy, and dose of ECUR-506 in male babies with neonatal-onset OTC deficiency. The primary objective is to evaluate the safety, tolerability, and efficacy of up to three dose levels of ECUR-506 following intravenous (IV) administration of a single dose.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study drug, ECUR-506, is an investigational gene editing therapy. Gene editing is an approach used to repair, replace, or introduce functional copies of genes that are not working properly. ECUR-506 contains a functional copy of the OTC gene, along with a gene to encode an editing enzyme that enables insertion of the OTC gene into the genome. The study drug is administered as a single IV infusion. Because genes cannot enter cells on their own, ECUR-506 uses a delivery system based on adeno-associated virus (AAV), a commonly used viral vector, to transport the genetic material into cells.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
New South Wales
-
Sydney, New South Wales, Australie
- The Children's Hospital at Westmead
-
-
Victoria
-
Melbourne, Victoria, Australie, 3052
- The Royal Children's Hospital
-
-
-
-
-
Barcelona, Espagne, 08950
- Hopsital Sant Joan de Deu
-
Madrid, Espagne, 28041
- Hospital Universitario 12 de Octubre
-
-
-
-
-
London, Royaume-Uni
- Great Ormond Street Hospital
-
Newcastle upon Tyne, Royaume-Uni
- The Newcastle upon Tyne Hospitals NHS Foundation Trust- Great North Children's Hospital
-
-
-
-
California
-
Los Angeles, California, États-Unis, 90095
- UCLA Mattel Children's Hospital
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Children's Hospital of Colorado, Anshutz Medical Campus
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Emory University School of Medicine
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
New York
-
New York, New York, États-Unis, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Oregon Health and Science University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
- Male sex
- Gestational or adjusted (corrected) gestational age ≥ 37 weeks
- Age at screening is 24 hours to 7 months
- Weight ≥ 3.5 kg and ≤ 13.5 kg at screening
- Has received age-appropriate vaccinations
- Genetically confirmed OTCD defined by genetic confirmation of an OTC variant (pathogenic or likely pathogenic) associated with severe neonatal OTCD defined below in Inclusion Criteria #7 or has the same OTC variant as a family member who had severe neonatal OTCD within first week of life.
- Severe neonatal OTCD defined by hyperammonemic crisis with elevated ammonia level of >560 μmol/L and clinical symptoms within first week of life, and currently receiving treatment with both dietary protein restriction and nitrogen scavenger therapy.
- Current or historical biochemical profile consistent with OTCD
- Participant's parent(s)/LAR must be able to comprehend and be willing to provide a signed IRB/IEC-approved ICF.
Key Exclusion Criteria:
- Neonatal diagnosis of severe to profound Hypoxic Ischemic Encephalopathy due to birth injury
- Requiring urgent liver transplant due to liver failure as assessed by the PI.
- Contiguous gene deletion involving the OTC gene and including at least the CYBB gene on the telomeric side or the TSPAN7 gene on the centromeric side.
- Known or suspected major organ injury/dysfunction/anomalies.
- Vital sign and laboratory abnormalities outside of reference ranges.
- Treatment with any other gene therapy or gene editing therapy
- Co-enrollment in any other study unless approved by the sponsor.
- Any condition, that in the opinion of the Investigator, would compromise the safety of the participant or study data
- Documented vertical transmission of HepA/HepB/HepC
- Documented in-utero teratogen, substance, and/or alcohol exposure, which in the opinion of the Investigator may increase the participant's risk of developmental delays, congenital anomalies, and/or significant medical complications
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Low Dose Level
Participants will receive the Low Dose of ECUR-506 delivered one time via IV Infusion. |
ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene. |
|
Expérimental: Intermediate Dose Level
Participants will receive an intermediate dose of ECUR-506 delivered on time via IV infusion |
ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene. |
|
Expérimental: High Dose Level
Participants will receive a higher dose of ECUR-506 delivered one time via IV infusion. |
ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Treatment-emergent adverse events (incidence, severity, seriousness, and relatedness)
Délai: Over 24 weeks post infusion
|
Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, Pediatric Neurologist exam parameters, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period. AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity following the administration of the study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related. |
Over 24 weeks post infusion
|
|
Physical exam parameters
Délai: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes PI assessment of General Appearance, Dermatological, HEENT, Lymphatic, Respiratory, Cardiovascular, Gastrointestinal, Musculoskeletal, Neurological (Cranial Nerve Function, Motor System Function, Sensory System Function, Primitive Reflexes)) |
Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Vital sign parameters
Délai: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes PI assessment of Systolic Blood Pressure, Diastolic Blood Pressure, Pulse Rate, Respiratory Rate, Temperature) |
Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Pediatric neurologist exam parameters
Délai: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes Pediatric Neurologist assessment of Neurological status by review of Cranial Nerve Function, Motor System Function, Sensory System Function, Primitive Reflexes.) |
Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Blood safety tests including hematology, serum chemistry, liver function tests, coagulation tests
Délai: as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Blood Safety tests to be reviewed in relation to established normal ranges for each assessment for the applicable age group) |
as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Urinalysis evaluations
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period. AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity following the administration of the study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
12 lead ECG parameters
Délai: as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes PI review of Heart Rate, PR Interval, RR Interval, QRS Duration, QT Interval, QTcF Interval, Overall Interpretation) |
as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Complete clinical response
Délai: Over 24 weeks post infusion
|
Discontinuation of scavenger medication for a minimum duration of 28 days without reductions in prescribed daily protein intake during this time period by end of study. |
Over 24 weeks post infusion
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of HAEs/person-year
Délai: Day 1 post dose through Week 24
|
Key Secondary Endpoint: Pharmacodynamics and Efficacy |
Day 1 post dose through Week 24
|
|
qPCR measurement to evaluate the clearance of both vectors in body fluids over time
Délai: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacokinetics |
Over 24 weeks post infusion
|
|
Incidence of hyperammonemic episode (HAE)
Délai: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Incidence and number of hyperammonemic episodes (HAE/HAC) resulting in hospitalization
Délai: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Overall and by hospitalization severity (Mild: adjustment of dietary protein intake and oral scavenger medication / Moderate: cessation of dietary protein intake and initiation of IV scavenger therapy / Severe: requirement for hemodialysis)
Délai: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy. |
Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants
|
|
Duration of hospitalization for each HAE/HAC
Délai: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Requirement for Intensive Care Unit (ICU) care during hospitalization for each HAE/HAC
Délai: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Time to liver transplant from dosing to end of study (EOS)
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Supportive Secondary Endpoint: Efficacy |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Transplant free survival
Délai: Time to lever transplant or any-cause death from dosing to EOS
|
Supportive Secondary Endpoint: Efficacy |
Time to lever transplant or any-cause death from dosing to EOS
|
|
Overall survival
Délai: Time to any-cause death from dosing to EOS
|
Supportive Secondary Endpoint: Efficacy |
Time to any-cause death from dosing to EOS
|
|
Achieving and maintaining complete clinical response through end of study
Délai: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Efficacy |
Over 24 weeks post infusion
|
|
Scavenger drug dose
Délai: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Efficacy |
Over 24 weeks post infusion
|
|
Dietary protein intake g/kg/day
Délai: Supportive Secondary: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Efficacy |
Supportive Secondary: Over 24 weeks post infusion
|
|
Blood urea nitrogen measurements
Délai: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics |
Over 24 weeks post infusion
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Clinical Response (CR) defined as reduction in baseline standard of care therapy
Délai: Assessed at Week 24
|
Efficacy |
Assessed at Week 24
|
|
Serum Neurofilament Light Chain
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Safety |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Number of participants with antibodies to AAVrh79 capsid in blood
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Number of participants with antibodies to hOTC transgene in blood
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Number of participants with antibodies to M2PCSK9 transgene in blood
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Incidence and time to medical management adjustments based on iECURE guidance (protein diet or scavenger medication)
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Efficacy |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Fasting plasma ammonia
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Fasting plasma citrulline and fasting plasma glutamine levels
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Serum PCSK9
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Urinary excretion of phenylacetate metabolites
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Urinary phenylacetate (mcg/mL), urinary phenylacetylglutamine (mcg/mL), urinary phenylacetate/ phenylglutamine ratio. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Urinary excretion of orotic acid metabolites.
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Urinary orotic acid (mmol/ mol creatinine), urinary uracil (mmol/mol creatinine). |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Urinary nitrogen to urinary creatinine ratio.
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Urinary nitrogen to urinary creatinine ratio (mg/dL) |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Change from baseline at Week 24 post infusion in length.
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Length measured in centimeters. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Change from baseline at Week 24 post infusion in weight.
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Weight measured in kilograms. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Percent liver transduction via ISH/IF (in-situ hybridization / Immunofluorescence)"at Wk 24 collected by liver biopsy.
Délai: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
|
Assess the potential on and "off" target editing by amplicon-seq in liver tissue samples of participants who received ECUR-506.
Délai: The following will be assessed at week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at week 24 if liver biopsy tissue sample is sufficient.
|
|
Assess potential off-target editing with AAV vector ITR insertion by ITR-seq in liver tissue samples of participants who received ECUR-506
Délai: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
|
Assess for potential genetic changes in the liver tissue, collected by liver biopsy, through long read sequencing, in participants who have received ECUR-506
Délai: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
|
With an observed genetic safety signal, genetic analysis of Whole Blood DNA may be performed on samples collected and stored at screening and week 24, in the event of an observed genomic safety signal.
Délai: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
Safety |
Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
|
Change from baseline at Week 24 post infusion in Bayley Scales of Infant and Toddler Development 4th Ed (BSID-4) for the Cognitive, Language, and Motor scales
Délai: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Total Raw Scores, Growth Score Values (GSVs), and Age Equivalent Scores will be analyzed; Raw Scores range 0-162; GSVs range 428-599; Age Equivalent Scores range 1-42 months; a higher score reflects a higher level of skill. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Quality of Life, as measured by the Pediatric QOL inventory Infant Scale (PedsQL-IS)
Délai: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
Quality of Life |
Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: George Diaz, M.D., Ph.D, iECURE, Inc.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- Maladies du système nerveux
- UCD
- Maladies du système nerveux central
- Maladie du foie
- Maladies génétiques, innées
- Lié à l'X
- Ammoniac
- Néonatal
- Maladies du cerveau
- Maladies métaboliques
- Métabolisme
- Métabolisme, erreurs innées
- Troubles du cycle de l'urée
- Greffe du foie
- Troubles métaboliques héréditaires
- Maladies cérébrales, métaboliques, innées
- Maladies génétiques liées à l'X
- Inné
- Erreurs innées
- OTC
- Maladies cérébrales métaboliques
- Carence OTC
- OTCD
- Ornithine
- Transcarbamylase
- Déficit en ornithine transcarbamylase
- Hyperammoniémie
- Métabolisme des acides aminés, erreurs innées
- Haute ammoniac
- NH4
- Troubles neurométaboliques
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Maladies du système digestif
- Maladies et anomalies congénitales, héréditaires et néonatales
- Conditions pathologiques, signes et symptômes
- Maladies nutritionnelles et métaboliques
- Maladies génétiques, innées
- Maladies du foie
- Maladies du cerveau
- Maladies du système nerveux
- Maladies du système nerveux central
- Maladies métaboliques
- Métabolisme, erreurs innées
- Maladies cérébrales métaboliques
- Maladies génétiques liées à l'X
- Déficit en ornithine carbamoyltransférase
- Troubles du cycle de l'urée, innés
- Métabolisme des acides aminés, erreurs innées
- Hyperammoniémie
- Maladies cérébrales, métaboliques, innées
Autres numéros d'identification d'étude
- ECUR-506-OTC-101
- OTC-HOPE (Autre identifiant: iECURE, Inc.)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .